Lloyds CMO: Uncertainty is the price of an interesting career October 1, 2026 We dig into the memory bank of the City's great and good. Today, Suresh Balaji, chief marketing office at Lloyds, takes us through his career.
Powerful Medical and corpuls Partner to Bring Queen of Hearts AI-Powered Heart Attack Detection to Prehospital Care October 1, 2026 Queen of Hearts, the AI ECG model that detects heart attacks standard criteria miss, will be integrated into corpuls devices and telemedicine systems used by emergency care professionals in over 70 countries globally
Hims & Hers Names Chief Medical Officers in the UK and Australia, Deepening its Investment in Local Clinical Leadership October 1, 2026 Kultar Garcha, MD, joins as Chief Medical Officer of the UK and EMEA, and Matt Vickers, FRACGP, MBBS, BMedSci, AICGG, is named Chief Medical Officer of Hims Australia, guiding clinical strategy as Hims & Hers continues to expand internationally
Burnham’s ‘costly’ policy agenda sparks investor nerves October 1, 2026 Andy Burnham’s “costly” policy agenda and the resurgent threat of inflation are weighing on investors’ appetite for the UK, according to a closely-watched survey of top money managers, which also revealed waning hopes of a rebound in London’s IPO market this year. Berenberg’s Investor Barometer, which polled 300 international investors managing a combined $1 trillion, [...]
MSG Sport to spin New York Knicks and Rangers into NYSE-listed firms October 1, 2026 Directors at Madison Square Garden Sports Corp have approved plans to spin off the organisation’s New York Rangers and New York Knicks franchises into separate public firms. The move will make the NBA-winning New York Knicks the first publicly traded basketball team in nearly a quarter of a century. The New York Knicks NBA spin-off [...]
Global bond sell-off: Headache for Healey as gilt yields top six per cent October 1, 2026 The yield that the UK government pays on its 30-year government bond rose above six per cent for the first time in this millennium, putting Chancellor John Healey in a collision course with markets. Long-term gilt yields, which determine the size of UK government borrowing costs, skimmed 6.04 per cent in the early hours of [...]
ROYC Group Launches ROYC Operating System as a Standalone Enterprise Software Platform October 1, 2026 ROYC Group today announced the launch of ROYC Operating System (ROYC OS) as a standalone software platform for fund managers, banks and wealth managers across private markets. The software is now available separately from ROYC’s existing structuring, fund operations and distribution services. Proven in production, at scale ROYC used its structuring and fund operations experience [...]
Dunbar Pharma Supplies API for UK’s First Plant-Derived Dronabinol Oral Spray October 1, 2026 Irish manufacturer’s API used in additional oral formulation through IPS Pharma; Company to expand Athlone production in 2027
EADV 2026: Long-Term Disease Control for up to Five Years in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab October 1, 2026 Late-breaking results from the Phase 3b ADlong clinical study presented by Almirall at EADV 2026 show treatment outcomes over time with up to five years of lebrikizumab treatment in moderate-to-severe atopic dermatitis: sustained efficacy and safety demonstrated by 92.9% of patients achieving EASI-75 and 73.8% achieving EASI-90 at the end of the study (week 108)1. At week 108 of continuous treatment, 66.7% of patients achieved clear or almost-clear skin, while 78.0% reported an absolute pruritus score of four or less on the Pruritus Numerical Rating Scale1, indicating low levels of itch, one of the most bothersome symptoms for patients. The ADlong study reflects the ongoing commitment to generating long-term evidence for lebrikizumab and the opportunity to achieve long-term disease control in AD treatment. Almirall’s scientific presence at EADV 2026 includes more than 20 abstracts across atopic dermatitis, psoriasis and actinic keratosis, alongside three expert-led events: two symposia and an interactive AD Morning Hub.
Orifarm Unveils 2031 Strategy to Accelerate Growth Across Europe, With Significant Expansion in Generics October 1, 2026 With its five-year strategy, Fit to Scale, Orifarm sets out an ambitious path to scale across Europe, including a major expansion of its prescription medicines business from a Nordic footprint to a broader European platform. The strategy aims to double EBITDA to €300m and generate more than €3bn in revenue by 2031, marking the next [...]